Drugs / Compound Sodium Alginate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02623062 Comparator | Dec 2013 → Mar 2016 | gastroesophageal reflux disease | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Sodium Alginate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02623062 ↗ |
| Route | Oral | “Compound Sodium Alginate Oral Suspension sachets (20ml four times daily)” NCT02623062 ↗ |